Change in diabetic retinopathy through 2 years secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab
Susan B. Bressler, Danni Liu*, Adam R. Glassman, Barbara A. Blodi, Alessandro A. Castellarin, Lee Merrill Jampol, Paul L. Kaufman, Michele Melia, Harinderjit Singh, John A. Wells
Dive into the research topics of 'Change in diabetic retinopathy through 2 years secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab'. Together they form a unique fingerprint.